Methods and Compositions for the Diagnosis of Neuroendocrine Lung Cancer
Posted Nov 03 2009 4:00pm
Description of Invention: The technology relates to the use of cDNA microarrays to facilitate the identification of pulmonary neuroendocrine tumors. In order to identify molecular markers that could be used to classify pulmonary tumors, the inventors examined the gene expression profiles of clinical samples from patients with small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), and typical carcinoma (TC) tumors by cDNA microarray analysis to detect hybridization between cDNA from tumor cells and DNA from a panel of 8,897 human genes. Gene expression was found to be nonrandom and to exhibit highly significant clustering that divided the tumors into their assigned World Health Organization (WHO) classification with 100% accuracy. The inventors concluded that pulmonary neuroendocrine tumors could be classified based on the genome-wide expression profile of the clinical samples without further manipulations.
Method to differentiate three types of pulmonary neuroendocrine tumors
Method to diagnose pulmonary neuroendocrine cancer
Advantages: Accurate, rapid, easy to use diagnostic to stratify patients according pulmonary tumors
Development Status: The technology is currently in the pre-clinical stage of development.
P He et al. Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Human Pathol. 2004 Oct;35(10):1196-1209. [ PubMed abs ]
Licensing Status: Available for licensing.
Portfolios: Cancer Cancer - Diagnostics Rare Diseases
For Additional Information Please Contact: Jennifer Wong NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4633 Fax: 301-402-0220